The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the ...

Asthma is a heterogeneous disease and can be classified by histologic background (eosinophilic or non-eosinophilic) or underlying mechanisms (allergic or non-allergic), with approximately half of ...

A large percentage of patients with mild-to-moderate asthma have persistently non-eosinophilic disease which may not respond to currently available anti-inflammatory treatments, according to a new ...

A large percentage of patients with mild-to-moderate asthma have persistently non-eosinophilic disease which may not respond to currently available anti-inflammatory treatments, according to a new ...

Eosinophilic patients had a median eosinophilic count of 440 cells/µL (interquartile range [IQR], 363-569) whereas non-eosinophilic patients had a median eosinophilic count of 90 cells/µL (IQR ...

So there's eosinophilic, or T2, asthma and then there's noneosinophilic, or non-T2, asthma. And the eosinophilic asthmatics, or T2 asthmatics, are the patients we classically think of as having ...

Based on the Heaney algorithm, 69.6% were grade 3 and 20.8% were grade 2, both considered likely eosinophilic; 16.8% were grade 1, or less likely to be eosinophilic; and 5.9% were grade 0, or non ...

Mechanisms of non-T2 asthma, including neutrophilic inflammation and airway hyperresponsiveness. ... indicating a unique role in non-eosinophilic asthma pathology via a positive feedback loop.

Canadian patients with eosinophilic asthma can currently choose from 4 targeted monoclonal antibodies approved by Health Canada, including mepolizumab and reslizumab, which target IL-5, and ...

The up to 50% of asthma patients with non-eosinophilic disease, as defined by low levels of the eosinophil white blood cells, have limited effective treatment options.

In a previous study, we showed that non-eosinophilic asthma phenotypes induced by LPS-containing allergens is mediated by the IL-12-STAT4-IFN-γ axis (Kim et al., 2007).